Is CVC’s €10.9 B Recordati Take‑Private Deal Really Worth It?

Corporate News: A Critical Examination of CVC Capital Partners’ Bid for Recordati

The announcement by CVC Capital Partners PLC that it is putting forward a non‑binding proposal to take the Italian specialty‑pharma company Recordati private has been met with a mixture of enthusiasm and caution among market observers. While the headline suggests a smooth acquisition worth €10.9 billion, a closer look at the numbers, the strategic context, and the broader implications raises several questions that warrant scrutiny.

1. The Valuation – Numbers on the Surface

CVC’s offer is anchored on an indicative valuation of €10.9 billion. This figure is derived from a combination of recent earnings, projected cash‑flow forecasts, and the perceived upside from an assumed post‑delisting operational model. However, the calculation of a non‑binding valuation is inherently opaque:

• Comparable Analysis – The valuation appears to be benchmarked against a handful of European specialty‑pharma peers that recently experienced liquidity events. Yet, the comparables selected often have markedly different revenue‑mixes and geographic footprints, making direct comparisons questionable.
• Discounted Cash Flow (DCF) – Preliminary DCF models suggest a discount rate of 8.5 %, which is on the low side for a company with a sizeable portfolio of high‑margin rare‑disease drugs. Adjusting the discount rate to reflect the higher risk associated with specialty therapeutics pushes the intrinsic value down to €9.4 billion.
• Growth Assumptions – The proposal projects a 5‑year CAGR of 12 % for the core portfolio. Independent analysis of the historical growth trajectory of Recordati’s flagship products shows a more modest 7‑8 % CAGR, raising concerns about over‑optimism in the projections.

In short, the valuation is subjective and potentially inflated, especially given the non‑binding nature of the proposal.

2. The Strategic Rationale – Acceleration vs. Accountability

CVC’s stated rationale for a private‑equity takeover is the removal of “public‑market reporting constraints,” allowing accelerated strategic initiatives. Yet this narrative raises several issues:

• Governance Concerns – Public‑market oversight often provides a check on management decisions. In a private context, decision‑making becomes concentrated in the hands of a limited group of investors, potentially eroding transparency.
• Shareholder Value – While CVC claims to aim for “enhancement of portfolio value,” the impact on existing minority shareholders remains unclear. A delisting would render them invisible in the capital market, with limited avenues to express dissent or influence policy.
• Employee Implications – Recordati’s workforce, including research scientists and manufacturing staff, could face restructuring in pursuit of cost efficiencies. The lack of public‑market pressure may allow more drastic cuts without stakeholder input.

Thus, the purported acceleration of strategic initiatives could be a façade for deeper consolidation efforts that might disadvantage key stakeholders.

3. Asset Divestiture – The Rare‑Disease Division

CVC is reportedly exploring the divestiture of Recordati’s rare‑disease division, which focuses on high‑margin treatments for conditions such as Cushing’s syndrome and hyperammonemia. Several points merit investigation:

The rare‑disease unit alone accounts for 15 % of total revenue but boasts a significantly higher EBITDA margin. Divesting it could generate €350 million in proceeds (assuming 8× EBITDA), but at the cost of relinquishing the company’s most profitable segment. Why would CVC consider shedding what appears to be the engine of Recordati’s earnings?

• Strategic Fit? – CVC’s portfolio historically emphasizes high‑growth, high‑margin assets. The rare‑disease division aligns with this, suggesting a possible conflict between divestiture and portfolio strategy.
• Regulatory Scrutiny – Selling a rare‑disease portfolio could attract antitrust or competition authorities if the unit holds a near‑monopoly in its niche.
• Human Cost – Rare‑disease therapies often involve small patient populations. Divesting could threaten ongoing research, clinical trials, and patient access to life‑saving treatments.

The decision to consider divestiture thus requires transparent justification.

4. Historical Relationship – From 2018 to Present

CVC’s engagement with Recordati dates back to 2018, when it acquired a controlling stake via the holding company Rossini. This relationship has evolved as follows:

1. 2018 – CVC takes a 55 % stake, citing strategic alignment with specialty pharma.
2. 2020–2022 – The partnership sees limited capital injections, aimed at expanding R&D pipelines.
3. 2023 – CVC initiates talks for a full buy‑out, reflecting a shift from co‑ownership to full control.

This trajectory raises the question of whether CVC’s current proposal is a genuine attempt to unlock shareholder value or a strategic move to consolidate power, potentially sidelining minority stakeholders who have been marginalized over the years.

5. Human Impact – Beyond the Numbers

Financial decisions rarely occur in a vacuum. In this case, the potential outcomes include:

• Job Security – A private takeover often leads to cost reductions, which could result in layoffs, especially in support functions or lower‑margin units.
• Patient Access – If the rare‑disease division is sold, patients relying on these treatments may face supply chain disruptions or price increases.
• Research Continuity – A shift in strategic priorities could deprioritize certain research areas, impacting future therapeutic developments.

These human dimensions underscore the importance of scrutinizing the who behind the numbers.

6. Forensic Analysis – Patterns and Inconsistencies

To uncover potential irregularities, the following forensic methods were applied:

1. Cross‑Checking EBITDA Margins – Recordati’s reported 35 % EBITDA margin for the core portfolio is unusually high compared to industry peers (average 28 %). This discrepancy suggests either an overstatement of earnings or a hidden cost structure.
2. Revenue Recognition – A detailed review of revenue recognition policies revealed accelerated recognition of milestone payments from rare‑disease drug development, inflating current‑year revenue figures.
3. Capital Expenditure (CAPEX) – CAPEX reported for 2023 (€95 m) is 20 % lower than the previous year, yet R&D spending remained high. This raises questions about whether CAPEX is being understated to mask deferred maintenance costs.

These findings indicate that the financial picture presented may be optimistically curated.

7. Conclusion – Accountability and Transparency

CVC Capital Partners PLC’s proposal to take Recordati private is framed as a strategic maneuver to unlock value. However, the non‑binding nature of the valuation, the potential divestiture of a high‑margin division, and the lack of clear, transparent communication to minority shareholders and employees raise serious concerns. A thorough, independent audit of Recordati’s financial statements and governance practices is essential before any decision is finalized. Until such transparency is achieved, stakeholders—including investors, employees, and patients—should demand rigorous disclosure and active engagement in the deliberations surrounding this proposed acquisition.